Welcome to our dedicated page for Sintx Technologies SEC filings (Ticker: SINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Silicon-nitride ceramics may power next-generation implants, but the disclosures behind SINTX Technologies can feel just as dense as the material itself. Revenue recognition for biomedical devices, R&D on antipathogenic coatings, and regulatory milestones sprawl across hundreds of pages—leaving investors asking where to even begin.
Stock Titan’s AI answers that challenge. Our platform ingests every SINTX filing the moment it hits EDGAR and delivers plain-English takeaways. Need the SINTX quarterly earnings report 10-Q filing? We highlight segment sales and cash-burn trends in seconds. Curious about SINTX insider trading Form 4 transactions? Get real-time alerts on each scientist or executive stock move, plus context on historical patterns. Struggling with the 10-K? Click the SINTX annual report 10-K simplified summary for risk-factor translations and silicon-nitride market analysis.
Every document type is covered:
- 8-K material events explained—follow FDA clearances or new licensing deals.
- Proxy statement executive compensation—see how R&D milestones drive bonuses.
- Form 4 insider transactions real-time—track confidence from the lab to the boardroom.
Whether you’re benchmarking gross margins, monitoring SINTX earnings report filing analysis, or simply understanding SINTX SEC documents with AI, Stock Titan turns technical ceramics jargon into actionable insight. Stop combing through PDFs and start focusing on decisions that matter.
On 22 Jul 2025, SINTX Technologies (SINT) filed a Form 8-K (Item 7.01) to furnish a press release announcing it has submitted a 510(k) application to the U.S. Food & Drug Administration for silicon-nitride foot & ankle medical devices. The disclosure is informational only and is not deemed “filed” for liability purposes. No financial statements, revenue guidance, or cost estimates accompany the submission. While the filing marks a key regulatory milestone that could enable U.S. commercialization, the company did not provide an expected review timeline, market size, or projected financial impact.
SINTX Technologies (NASDAQ:SINT) filed an 8-K announcing a definitive Asset Purchase Agreement signed 23 Jun 2025 with Sinaptic Surgical to acquire substantially all foot-and-ankle implant assets. Consideration is warrants for up to 325,000 SINT shares at $6.30, vesting on FDA 510(k) clearance and cumulative revenue milestones of $2.5-$15 million, and expiring after five years. Sinaptic will also purchase 216,450 shares at $3.465 in a private placement. Upon exceeding $15 million net revenue within four years, Sinaptic earns a 5 % royalty on related sales for two years. Closing is targeted for 1 Jul 2025, subject to customary conditions, and SINTX will file a resale registration within 90 days. The deal provides immediate capital, broadens SINTX’s product pipeline, and aligns future dilution with commercial success.
Director Mark Lewis Anderson of Sintx Technologies has reported a significant insider purchase of company shares. On June 18, 2025, Anderson acquired 10,000 shares of Common Stock at a price of $3.30 per share, representing a total investment of $33,000.
Following this transaction, Anderson's direct ownership increased to 15,000 shares of Sintx Technologies common stock. The purchase was executed as a standard market transaction and was reported through Form 4 filed with the SEC on June 28, 2025.
This insider buying activity by a board member could be viewed as a positive signal about the company's prospects, as directors often purchase shares when they believe the stock is undervalued or expect positive developments. The transaction was authorized through power of attorney by Kevin Ontiveros.
FAQ
What is the current stock price of Sintx Technologies (SINT)?
What is the market cap of Sintx Technologies (SINT)?
